Estimated Sustainable Cost-Based Prices for Diabetes Medicines
An erratum to this article was published (JAMA Netw Open, 1 Apr 2024 ↗)
Authors' conclusion
High prices limit access to newer diabetes medicines in many countries. The findings of this study suggest that robust generic and biosimilar competition could reduce prices to more affordable levels and enable expansion of diabetes treatment globally.
Study context
- Population
- Insulins, SGLT2i and GLP-1 RA; current prices in 13 countries of different income levels and regions, collected January 202313 countries
- Comparison
- Estimated sustainable cost-based prices (CBPs) vs current market prices of insulins, SGLT2i and GLP-1 RA
- Outcome
- Estimated CBPs; lowest current market prices (2023 US dollars)
Methodological detailscost-of-manufacturing modelling, weighted least-squares regression model
- Cost-of-manufacturing modelling
- Weighted least-squares regression model
Main finding
As reported in the abstract
Estimated CBPs
- Insulin, reusable pen, basal-bolus regimen: human insulin
- $96 per year
- Insulin, reusable pen, basal-bolus regimen: insulin analogues
- $111 per year
- Twice-daily injections of mixed human insulin
- $61 per year
- Once-daily basal insulin (T2D): human insulin
- $50 per year
- Once-daily basal insulin (T2D): insulin analogues
- $72 per year
- SGLT2i (except canagliflozin)
- $1.30 to $3.45 per month
- Canagliflozin
- $25.00-$46.79
- GLP-1 RA
- $0.75 to $72.49 per month
Original publication
Estimated Sustainable Cost-Based Prices for Diabetes Medicines. JAMA Netw Open. Published 4 March 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →